Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.

Nonetheless, those patients who had ≥12 months of PFS during prior palbociclib‐based therapy only had a numerical trend towards PFS improvement compared with those patients who had less than 12 months of PFS during prior palbociclib‐based therapy (median PFS: 7.0 vs. 5.0 months, log‐rank p = 0.931).

also in 337 other papers